Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome [3]

Annals of the Rheumatic Diseases

Volumn 67, Issue 2, 2008, Pages 278-

  Delluc, A ^a,b   Limai, N ^a,b   Puechal X ^c   Frances C ^a,b   Piette, J C ^a,b   Cacoub, P ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Centre Hospitalier du Mans   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; DAPSONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; CASE REPORT; CELL INFILTRATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISTOPATHOLOGY; HUMAN; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; RECURRENT FEVER; SKIN DEFECT;

DERMATOLOGIC AGENTS; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; SWEET'S SYNDROME; TREATMENT OUTCOME;

EID: 38749150377     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.068254     Document Type: Letter

References (5)

1. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 2003;42:761-78.
2. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005;52:1960-7.
3. Bourke JF, Jones JL, Fletcher A, Graham-Brown RA. An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1 in 12 cases of Sweet's syndrome. Br J Dermatol 1996;134:705-9.
4. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343:732-4.
5. Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 1998;39:940-3.